Anti-JM4/PRAF2 antibody (ab53113)
Key features and details
- Rabbit polyclonal to JM4/PRAF2
- Suitable for: IHC-P, WB
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-JM4/PRAF2 antibody
See all JM4/PRAF2 primary antibodies -
Description
Rabbit polyclonal to JM4/PRAF2 -
Host species
Rabbit -
Specificity
ab53113 detects endogenous levels of total JM4/PRAF2 protein.
-
Tested Applications & Species
See all applications and species dataApplication Species IHC-P HumanWB Human -
Immunogen
Synthetic peptide corresponding to Human JM4/PRAF2.
-
General notes
This product was previously labelled as JM4
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol (glycerin, glycerine), 0.87% Sodium chloride, PBS
Without Mg+2 and Ca+2 -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Images
-
All lanes : Anti-JM4/PRAF2 antibody (ab53113) at 1/300 dilution
Lane 1 : Mouse spleen whole tissue lysate
Lane 2 : Mouse braint whole tissue lysate
Lane 3 : Mouse heart whole tissue lysate
Lane 4 : Mouse kidney whole tissue lysate
Lane 5 : Mouse liver whole tissue lysate
Lane 6 : Mouse embryonic fibroblasts lysate
Lysates/proteins at 40 µg per lane.
Secondary
All lanes : HRP-conjugated Goat anti-rabbit at 1/10000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 19 kDa
Observed band size: 22 kDa why is the actual band size different from the predicted?
Additional bands at: 55 kDa (possible non-specific binding)
Exposure time: 20 seconds
-
All lanes : Anti-JM4/PRAF2 antibody (ab53113) at 1/300 dilution
Lane 1 : LOVO cell extract
Lane 2 : LOVO cell extract with immunising peptide
Predicted band size: 19 kDa
Observed band size: 19 kDa
-
ab53113 at 1/50 dilution staining JM4/PRAF2 in human brain tissue by Immunohistochemistry, Paraffin embedded tissue, in the absence and presence of the immunising peptide.